Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor

Michael Froehner; Bettina Beuthien-Baumann; Dag-Daniel Dittert; Ulrich Schuler; Manfred P Wirth

doi:10.1007/s00280-005-0181-6

Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor

Cancer Chemother Pharmacol. 2006 Nov;58(5):716-8. doi: 10.1007/s00280-005-0181-6. Epub 2006 Feb 1.

Authors

Michael Froehner¹, Bettina Beuthien-Baumann, Dag-Daniel Dittert, Ulrich Schuler, Manfred P Wirth

Affiliation

¹ Department of Urology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Michael.Froehner@uniklinikum-dresden.de

PMID: 16450163
DOI: 10.1007/s00280-005-0181-6

Abstract

Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the--to our knowledge--first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.

Publication types

Case Reports

MeSH terms

Aged
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Benzamides
Disease Progression
Enzyme Inhibitors / pharmacology
Enzyme Inhibitors / therapeutic use
Humans
Imatinib Mesylate
Leydig Cell Tumor / drug therapy*
Leydig Cell Tumor / secondary
Male
Piperazines / pharmacology
Piperazines / therapeutic use*
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / pharmacology
Pyrimidines / therapeutic use*
Testicular Neoplasms / drug therapy*
Testicular Neoplasms / secondary
Treatment Failure

Substances

Antineoplastic Agents
Benzamides
Enzyme Inhibitors
Piperazines
Pyrimidines
Imatinib Mesylate
Protein-Tyrosine Kinases